Btk inhibitors in atherosclerosis

Abstract

In this issue of Blood, Busygina et al provide provocative evidence that there is a potential role for Bruton tyrosine kinase (Btk) inhibitors in inhibiting platelet aggregation specifically at the site of unstable atherosclerotic plaques.